Future Directions in mHSPC Management: An Evolving Treatment Landscape
Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.
Practical Considerations for Selecting and Administering Treatment in mHSPC
Expert panelists consider the possibility of taking a break from treatment given a patient’s response to therapy along with other unique management strategies in the setting of metastatic hormone-sensitive prostate cancer.
Patient Scenario 3: A 75-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer
In a third clinical scenario of metastatic hormone-sensitive prostate cancer, panelists discuss oligometastatic disease, radiation therapy, and the potential role for PSMA-PET scans.
Patient Scenario 2: A 65-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer
Centering focus on a second clinical scenario of metastatic hormone-sensitive prostate cancer, key opinion leaders identify treatment options based on variations in presentation.
mHSPC: Assessing Patient Response and Selecting 2L Therapy at Progression
Shared insight on strategies to monitor patient response to therapy and select second-line treatment when hormone-sensitive prostate cancer progresses.
mHSPC: Importance of Quality of Life and Multidisciplinary Care
After nuancing quality of life data with chemotherapy in metastatic hormone-sensitive prostate cancer, panelists consider the value of multidisciplinary care.
Selecting Between Doublet and Triplet Therapy in Newly Diagnosed mHSPC
Focused discussion on the respective roles of doublet and triplet regimens in patients newly diagnosed with metastatic hormone-sensitive prostate cancer.
Newly Diagnosed mHSPC: Factors Used to Inform Treatment Selection
Panelists reflect on molecular markers and other clinical factors that aid in the selection of best therapy for a patient with metastatic hormone-sensitive prostate cancer.
Patient Scenario 1: A 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer
Key opinion leaders in the field of prostate cancer management consider optimal molecular testing practices in a patient with metastatic hormone-sensitive disease.
Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.
Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.
Daniel P. Petrylak, MD, Says Maintenance Immunotherapy Has Become Standard Practice in Bladder Cancer
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.
Avelumab Maintenance for Urothelial Carcinoma: Real-World Evidence
Daniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”
Optimization of Genetic Testing for mCRPC
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Sequencing Therapy for mCRPC
Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.
Role of PSMA PET Imaging in mCRPC
Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.
Patient Case #2: Choosing Optimal Therapy in mCRPC
Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.
Treatment Options for High-Volume mCNPC
Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.
Role of Conventional Imaging vs PSMA PET in mCNPC
A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.
Patient Case #1: Treatment Selection in mCNPC
Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.
Polling Questions: Advanced Prostate Cancer
Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.
Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer
ONCOLOGY® editorial board member E. David Crawford, MD, and colleagues, propose a new model for guiding the treatment of prostate cancer that focuses on a “transitional state,” which occurs during the interval of progression to metastatic castration-resistant prostate cancer.
Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer
In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.
Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen–Targetable Pathways in Castration-Resistant Prostate Cancer
Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer
An 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.
New Agents for the Treatment of Advanced Bladder Cancer
This article will review select novel targets and approaches relevant to urothelial cancer.
ASCO: Role of Chemotherapy and Novel Targeted Agents in Prostate Cancer
As part of our coverage of ASCO's Annual Meeting, we discuss the role of chemotherapy in prostate cancer, as well as study results on novel targeted approaches and agents in development for prostate cancer that will be presented at the meeting.
Sequencing of Agents for Castration-Resistant Prostate Cancer
In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.
The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy
A 55-year-old woman with a history of metastatic melanoma in remission for 8 years presented to the emergency department with gross hematuria. A CT scan, ordered because the patient was in menopause, demonstrated a bladder tumor.
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases: Mechanism of Action of Radium-223 Chloride (Alpharadin) and Radiation
This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin).
2 Clarke Drive Cranbury, NJ 08512